Literature DB >> 23358486

Multiple sclerosis: reprogramming the immune repertoire with alemtuzumab in MS.

Heinz Wiendl1, Bernd Kieseier.   

Abstract

Results from two phase III trials show the potency of alemtuzumab—a T-cell and B-cell depleting antibody—in reducing clinical and paraclinical measures of disease activity in relapsing–remitting multiple sclerosis. The effects of this immunotherapeutic agent highlight the relevance of T lymphocytes in the early pathogenesis of disease.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23358486     DOI： 10.1038/nrneurol.2013.2

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN： 1759-4758            Impact factor:   42.937


  8 in total

1.  Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial.

Authors:  A J Coles; E Fox; A Vladic; S K Gazda; V Brinar; K W Selmaj; A Skoromets; I Stolyarov; A Bass; H Sullivan; D H Margolin; S L Lake; S Moran; J Palmer; M S Smith; D A S Compston
Journal:  Neurology       Date:  2012-03-21       Impact factor: 9.910

Review 2.  Immune mechanisms of new therapeutic strategies in multiple sclerosis-A focus on alemtuzumab.

Authors:  Luisa Klotz; Sven G Meuth; Heinz Wiendl
Journal:  Clin Immunol       Date:  2011-04-15       Impact factor: 3.969

3.  Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes.

Authors:  Alasdair J Coles; Edward Fox; Anton Vladic; Suzanne K Gazda; Vesna Brinar; Krzysztof W Selmaj; Ann Doan-Do Bass; Daniel R Wynn; David H Margolin; Stephen L Lake; Susan Moran; Jeffrey Palmer; M Shelton Smith; D Alastair S Compston
Journal:  Lancet Neurol       Date:  2011-04       Impact factor: 44.182

4.  Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.

Authors:  Jeffrey A Cohen; Alasdair J Coles; Douglas L Arnold; Christian Confavreux; Edward J Fox; Hans-Peter Hartung; Eva Havrdova; Krzysztof W Selmaj; Howard L Weiner; Elizabeth Fisher; Vesna V Brinar; Gavin Giovannoni; Miroslav Stojanovic; Bella I Ertik; Stephen L Lake; David H Margolin; Michael A Panzara; D Alastair S Compston
Journal:  Lancet       Date:  2012-11-01       Impact factor: 79.321

5.  Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.

Authors:  Alasdair J Coles; Cary L Twyman; Douglas L Arnold; Jeffrey A Cohen; Christian Confavreux; Edward J Fox; Hans-Peter Hartung; Eva Havrdova; Krzysztof W Selmaj; Howard L Weiner; Tamara Miller; Elizabeth Fisher; Rupert Sandbrink; Stephen L Lake; David H Margolin; Pedro Oyuela; Michael A Panzara; D Alastair S Compston
Journal:  Lancet       Date:  2012-11-01       Impact factor: 79.321

6.  IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H).

Authors:  Joanne L Jones; Chia-Ling Phuah; Amanda L Cox; Sara A Thompson; Maria Ban; Jacqueline Shawcross; Amie Walton; Stephen J Sawcer; Alastair Compston; Alasdair J Coles
Journal:  J Clin Invest       Date:  2009-06-22       Impact factor: 14.808

7.  Long-term follow-up of relapsing/refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H).

Authors:  M Walsh; A Chaudhry; D Jayne
Journal:  Ann Rheum Dis       Date:  2007-11-29       Impact factor: 19.103

8.  Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.

Authors:  Alasdair J Coles; D Alastair S Compston; Krzysztof W Selmaj; Stephen L Lake; Susan Moran; David H Margolin; Kim Norris; P K Tandon
Journal:  N Engl J Med       Date:  2008-10-23       Impact factor: 91.245
  8 in total
  24 in total

Review 1.  Neuroimmunotherapies Targeting T Cells: From Pathophysiology to Therapeutic Applications.

Authors:  Stefan Bittner; Heinz Wiendl
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

2.  Immune regulation by CD52-expressing CD4 T cells.

Authors:  Ban-Hock Toh; Tin Kyaw; Peter Tipping; Alex Bobik
Journal:  Cell Mol Immunol       Date:  2013-08-12       Impact factor: 11.530

Review 3.  [Monitoring of blood parameters under course-modified MS therapy : Substance-specific relevance and current recommendations for action].

Authors:  L Klotz; A Berthele; W Brück; A Chan; P Flachenecker; R Gold; A Haghikia; K Hellwig; B Hemmer; R Hohlfeld; T Korn; T Kümpfel; M Lang; V Limmroth; R A Linker; U Meier; S G Meuth; F Paul; A Salmen; M Stangel; B Tackenberg; H Tumani; C Warnke; M S Weber; T Ziemssen; F Zipp; H Wiendl
Journal:  Nervenarzt       Date:  2016-06       Impact factor: 1.214

Review 4.  Disease-modifying therapies and infectious risks in multiple sclerosis.

Authors:  Alexander Winkelmann; Micha Loebermann; Emil C Reisinger; Hans-Peter Hartung; Uwe K Zettl
Journal:  Nat Rev Neurol       Date:  2016-03-04       Impact factor: 42.937

5.  Molecular treatment effects of alemtuzumab in skeletal muscles of patients with IBM.

Authors:  Karsten Schmidt; Konstanze Kleinschnitz; Goran Rakocevic; Marinos C Dalakas; Jens Schmidt
Journal:  BMC Neurol       Date:  2016-04-16       Impact factor: 2.474

6.  [Alemtuzumab for relapsing-remitting multiple sclerosis. Results of two randomized controlled phase III studies].

Authors:  L Klotz; S G Meuth; B Kieseier; H Wiendl
Journal:  Nervenarzt       Date:  2013-08       Impact factor: 1.214

7.  Comparison of the antibacterial activity of Australian Terminalia spp. extracts against Klebsiella pneumoniae: a potential treatment for ankylosing spondylitis.

Authors:  Reece Courtney; Ian Edwin Cock
Journal:  Inflammopharmacology       Date:  2022-01-06       Impact factor: 4.473

8.  Induction and Donor Specific Antibodies in Low Immunologic Risk Kidney Transplant Recipients.

Authors:  Natalie M Bath; Arjang Djamali; Sandesh Parajuli; Didier Mandelbrot; Glen Leverson; Luis Hidalgo; Thomas Ellis; Jillian L Descourouez; Margaret R Jorgenson; Dave Hager; Dixon B Kaufman; Robert R Redfield
Journal:  Kidney360       Date:  2020-10-01

Review 9.  Modulation of IL-2Rα with daclizumab for treatment of multiple sclerosis.

Authors:  Heinz Wiendl; Catharina C Gross
Journal:  Nat Rev Neurol       Date:  2013-06-04       Impact factor: 42.937

10.  CD52-targeted depletion by Alemtuzumab ameliorates allergic airway hyperreactivity and lung inflammation.

Authors:  Pedram Shafiei-Jahani; Doumet Georges Helou; Benjamin P Hurrell; Lauriane Galle-Treger; Emily Howard; Christine Quach; Jacob D Painter; Marshall Fung; Richard Lo; Hooman Allayee; Omid Akbari
Journal:  Mucosal Immunol       Date:  2021-03-17       Impact factor: 7.313
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.